Genitourinary Oncology
Primary Dreicer, Robert
CRC: Drake, Jennifer
19-20484 PHAR B-701_U22
Stages: Any/all CT.GOV ID: NCT03123055
A Multi-Center, Single-Arm, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined with Atezolizumab in Subjects with Locally Advanced or Metastatic Urothelial Carcinoma who have Progressed Following Platinum-based Chemotherapy
Primary Dreicer, Robert
CRC: Drake, Jennifer
19-21029 Other: National PrE0807
Stages: II; III; IV A CT.GOV ID: NCT03532451
Thoracic Oncology
ID: NCT02716116
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Primary Gentzler, Ryan
CRC: Hockenberry, Gracie, Tubbs
18-20474 PHAR 20474
Stages: III B; IV CT.GOV ID: NCT02716116
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Primary: Ryan Gentzler
CRC:Hockenberry, Gracie, Tubbs
Stages: II B; III A CT.GOV ID: NCT03425643
Filed Under: Basic Research, Clinical Research